Challenges in TB control and the anticipated COVID-19 third wave: Way forward.
C Padmapriyadarsini, V Banurekha, V K Arora
Author Information
- C Padmapriyadarsini: ICMR-National Institute for Research in Tuberculosis, Chetput, Chennai, India. Electronic address: padmapriyadarsinic@nirt.res.in.
- V Banurekha: ICMR-National Institute for Research in Tuberculosis, Chetput, Chennai, India.
- V K Arora: Tuberculosis Association of India, India.
No abstract text available.
- Int J Infect Dis. 2021 Mar 11;:
[PMID: 33716198]
- Eur Respir J. 2020 Jul 9;56(1):
[PMID: 32444399]
- BMJ Glob Health. 2020 Nov;5(11):
[PMID: 33199280]
- Indian J Med Res. 2021 May&Jun;153(5&6):522-532
[PMID: 34643562]
- Eur Respir J. 2020 Aug 13;56(2):
[PMID: 32513784]
- Indian J Med Res. 2021 May&Jun;153(5&6):533-536
[PMID: 34643563]
- Monaldi Arch Chest Dis. 2020 Jul 22;90(3):
[PMID: 32697060]
Antitubercular Agents
COVID-19
Disease Eradication
Disease Management
Humans
India
Medication Adherence
Missed Diagnosis
SARS-CoV-2
Tuberculosis
